Post-treatment improvement of NK cell numbers predicts better survival in myeloma patients treated with thalidomide-based regimens-Reference-Cited by-同舟云学术

Post-treatment improvement of NK cell numbers predicts better survival in myeloma patients treated with thalidomide-based regimens

Published:2019-06-05 Issue:3 Volume:110 Page:306-312
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Vela-Ojeda Jorge,Esparza Miriam America García-Ruiz,Majluf-Cruz Abraham,García-Chavez Jaime,Montiel-Cervantes Laura Arcelia,Reyes-Maldonado Elba,Hernandez-Caballero Alvaro,Rodríguez-González Maria Guadalupe

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/content/pdf/10.1007/s12185-019-02679-x.pdf

Reference26 articles.

1. Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med. 1997;336:1657–64.

2. Schutt P, Brandhorst D, Stellberg W, Poser M, Ebeling P, Müller S, et al. Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. Leuk Lymphoma. 2006;47(8):1570–82.

3. Nucci M, Anaisssie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis. 2009;49:1211–25.

4. Martinez-Lopez J, Blade J, Mateos MV, Grande C, Alegre A, Garcia-Laraña J, et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood. 2011;118(3):529–34.

5. Caligiuri MA. Human natural killer cells. Blood. 2008;112:461–9.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. What happens to regulatory T cells in multiple myeloma;Cell Death Discovery;2023-12-21

2. Cellular immunity in the era of modern multiple myeloma therapy;International Journal of Cancer;2023-06-12

3. N6‐methyladenosine regulators are potential prognostic biomarkers for multiple myeloma;IUBMB Life;2022-10-08

4. Prescription Patterns of Daratumumab in Patients with Multiple Myeloma in Underprivileged Circumstances: A Multicenter Experience in Mexico;Archives of Medical Research;2021-08

5. ADCC against MICA/B Is Mediated against Differentiated Oral and Pancreatic and Not Stem-Like/Poorly Differentiated Tumors by the NK Cells; Loss in Cancer Patients due to Down-Modulation of CD16 Receptor;Cancers;2021-01-11